NewEdge Wealth LLC Invests $95.26 Million in Gilead Sciences, Inc. $GILD

NewEdge Wealth LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, HoldingsChannel reports. The fund purchased 754,019 shares of the biopharmaceutical company’s stock, valued at approximately $95,263,000. Gilead Sciences makes up about 1.0% of NewEdge Wealth LLC’s portfolio, making the stock its 19th biggest holding.

Several other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth $15,393,785,000. Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. State Street Corp raised its stake in shares of Gilead Sciences by 1.9% in the 4th quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Gilead Sciences by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock valued at $3,399,734,000 after purchasing an additional 1,195,269 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 2.9%

Shares of GILD stock opened at $147.60 on Thursday. The stock has a 50-day simple moving average of $131.21 and a 200 day simple moving average of $136.51. The stock has a market capitalization of $183.02 billion, a P/E ratio of -55.28 and a beta of 0.32. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the previous year, the business earned $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, sell-side analysts expect that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Analysts Set New Price Targets

A number of equities analysts recently commented on GILD shares. Truist Financial decreased their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $133.00 to $155.00 in a report on Monday, July 6th. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Finally, Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the sale, the chief financial officer directly owned 165,646 shares of the company’s stock, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 82,000 shares of company stock worth $10,837,860. Insiders own 0.30% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Gilead, supporting the bullish view that the company’s recent momentum can continue. BMO Capital reaffirms Buy rating
• Positive Sentiment: Zacks Research raised estimates for third-quarter 2026 EPS to $1.93 from $1.84, fourth-quarter 2026 EPS to $2.14 from $2.07, and full-year 2027 EPS to $9.30 from $9.11. It also lifted estimates for parts of 2027, indicating improving expectations for near-term earnings. Gilead Sciences analyst estimates
• Positive Sentiment: Investors remain focused on Gilead’s expanding HIV portfolio. Biktarvy continues to anchor sales, while Yeztugo and additional pipeline programs could create new treatment and prevention opportunities. The company’s latest reported revenue also increased 10.6% year over year to $7.8 billion, exceeding expectations. Gilead’s expanding HIV portfolio
• Positive Sentiment: Gilead’s quarterly dividend of $0.82, equivalent to $3.28 annually, provides ongoing income support and reinforces its appeal to defensive and healthcare-focused investors.
• Neutral Sentiment: Zacks reduced estimates for first-quarter 2028 EPS to $2.14 from $2.21, second-quarter 2028 EPS to $2.27 from $2.33, and full-year 2028 EPS to $9.58 from $10.00. These cuts temper the otherwise positive near-term revisions and suggest some uncertainty about longer-term growth.
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares, while CFO Andrew Dickinson sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, limiting their significance, but the sales may modestly weigh on sentiment.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.